TARS
Tarsus Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.68B
P/E Ratio
—
EPS
$-1.11
Beta
0.53
52W High
$85.25
52W Low
$38.51
50-Day MA
$65.87
200-Day MA
$67.73
Dividend Yield
—
Profit Margin
-9.02%
Forward P/E
106.38
PEG Ratio
—
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
Fundamentals
| Revenue (TTM) | $535.08M |
| Gross Profit (TTM) | $427.95M |
| EBITDA | $-49.02M |
| Operating Margin | -3.78% |
| Return on Equity | -14.00% |
| Return on Assets | -5.87% |
| Revenue/Share (TTM) | $12.54 |
| Book Value | $8.07 |
| Price-to-Book | 7.67 |
| Price-to-Sales (TTM) | 5.01 |
| EV/Revenue | 4.408 |
| EV/EBITDA | -3.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 106.90% |
| Shares Outstanding | $43.02M |
| Float | $32.12M |
| % Insiders | 3.07% |
| % Institutions | 109.12% |
Historical Volatility
HV 10-Day
60.43%
HV 20-Day
49.73%
HV 30-Day
46.77%
HV 60-Day
42.02%
HV Rank
69.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($94.11 target)
1
Strong Buy8
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026